Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisArun J. Sanyal, Patricia R. Robuck, Naga Chalasani et al.|New England Journal of Medicine|2010Cited by 3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A. Neuschwander‐Tetri, Edward Doo, Rohit Loomba et al.|The Lancet|2014Cited by 2.2k
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitisKanji Yamaguchi, Anna Mae Diehl, Liu Yang et al.|Hepatology|2007Cited by 1k
Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human DiseaseMariana Verdelho Machado, Anna Mae Diehl|PLoS ONE|2015Cited by 381
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitisJu Dong Yang, Ayako Suzuki, Manal F. Abdelmalek et al.|Hepatology|2013Cited by 374